#exome sequencing in india

[newspatrolling]

Redcliffe Labs Study Unveils Rare Genetic Findings to Help Diagnose Neurological Disorder SENEBAC Syndrome in Children

● The research has uncovered a rare NRROS gene mutation linked to SENEBAC syndrome,

improving understanding of this severe neurological disorder in children.

● SENEBAC syndrome leads to seizures, developmental delays, and skill loss in children by disrupting brain protection against inflammation

Redcliffe Labs, a purpose-driven PAN India omnichannel diagnostics service provider, has achieved a significant breakthrough in understanding SENEBAC syndrome. The study, published in the American

Journal of Medical Genetics Part A, has documented a newly discovered genetic variant, c.720G>A,p.(Trp240*), in the NRROS gene. This discovery paves the way for earlier, more accurate diagnosis and personalized care approaches, instilling hope for improved patient outcomes.

The study focused on a 1-year-9-months female child whose symptoms began around nine months of age.To find the root cause of her condition, a team of doctors employed a focused genetic test called exome sequencing. This test examines specific areas of DNA responsible for making proteins. Through this

process, the team identified a previously unknown mutation in the NRROS gene, marking only the 12th

reported case of SENEBAC syndrome worldwide.

The SENEBAC syndrome is known to disrupt normal brain development and function, leading to serious symptoms such as frequent seizures, developmental delays, and the gradual loss of skills in young children. The syndrome is linked to mutations in the NRROS gene, which is crucial in protecting brain cells from damage caused by inflammation. In children affected by SENEBAC, a change in this gene weakens that protection, leaving the brain more susceptible to inflammatory harm that progressively impacts the child’s neurological health.

The report highlights that when the gene is altered due to a mutation, the microglia lose their ability to guard neurons effectively, resulting in the damage seen in SENEBAC syndrome. By highlighting this mechanism, the research findings emphasize the potential for targeted care approaches to protect

children’s brains that are better affected by inflammation, helping them manage symptoms and improve their quality of life.

Aditya Kandoi, CEO and Founder Redcliffe Labs, said, “We are dedicated to expanding our expertise across all the fields to provide society with the most advanced diagnostic solutions. Our focus is to broaden our specialized testing capabilities, including super-specialized pathology, to address the

increasingly complex needs of healthcare. Our team of experts actively contributes to medical knowledge,advancing diagnostic precision and patient care. We congratulate Dr. Himani Pandey for her crucial role in the recent SENEBAC syndrome research, which brings valuable insights into this rare neurodevelopmental condition. Contribution of Medical experts, Dr Himani Pandey and her team highlights the profound impact that focused research and expertise can have in shaping the future of diagnostics and patient care.”

Dr. Himani Pandey added, “Genomics is more than decoding DNA—it's the foundation for breakthroughs that redefine patient care. At Redcliffe Labs, we drive this revolution by combining cutting-edge research with unparalleled accuracy, delivering insights that empower precision medicine

and transformative healthcare solutions." The importance of this discovery goes beyond just identifying a mutation. By recognizing the exact genetic change responsible, doctors can more confidently diagnose SENEBAC syndrome when observing similar symptoms in other children. This accuracy helps families avoid a lengthy and uncertain diagnostic process and enables more timely care. Furthermore, knowing the genetic mutation can guide discussions with families on whether the condition might affect other children or future generations, giving parents essential information about their family’s health.

source : newspatrolling.com

[industrynewsupdates]

Bioinformatics Market Insights: Opportunities and Challenges

The global bioinformatics market was valued at USD 10.1 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 13.7% from 2023 to 2030. Several key factors are driving this growth, including the increasing demand for bioinformatics tools and software in novel drug research and development (R&D), as well as both private and public funding initiatives that are aimed at supporting R&D activities. Additionally, the introduction of user-friendly bioinformatics software such as RasMol, AUTODOCK, BALL, and Bioclipse has played a significant role in expanding the market. These software tools are widely used for the accurate analysis of biomarker discovery programs, which help in detecting toxicity during the early stages of the drug development process.

Advancements in DNA sequencing are also contributing to the growth of the bioinformatics market. For example, a study published by Stanford Medicine in January 2022 demonstrated a DNA sequencing technique capable of sequencing a human genome in about 8 hours. Such breakthroughs enhance the demand for genomics, thereby driving the bioinformatics sector. Bioinformatics applications in data storage and analysis are crucial for managing large volumes of genomic and proteomic data, which facilitate research in various fields, including aging, carcinogenesis, and genetic disease prevention. This growing capacity to store and analyze vast amounts of data is expected to significantly contribute to market expansion over the forecast period.

Gather more insights about the market drivers, restrains and growth of the Bioinformatics Market

Product Insights

In terms of product categories, the bio-content management segment held the largest market share in 2022, accounting for 39.6% of the total market revenue. This can be attributed to the widespread use of bioinformatics tools in database management. These tools facilitate efficient data sharing with external databases and resources, thereby promoting data integration across various platforms. Genetic sequence analysis platforms are also poised to experience significant growth, driven by the increased demand for whole-genome sequencing and exome sequencing technologies, which have become more affordable due to reduced sequencing costs.

Bioinformatics is governed by various guidelines set by organizations such as the Human Genome Variation Society (HGVS), the Genomic Data Commons (GDC), and the Minimum Information About a Microarray Experiment (MIAME). Compliance with these standards ensures improved data compatibility, sharing, and collaboration. A noteworthy example of collaboration in this field occurred in April 2022, when ATCC entered into a partnership with Qiagen to share sequencing data from its collection of animal and human cell lines. This partnership aims to create a comprehensive database to aid in the development of therapeutic targets and the understanding of new diseases, which is crucial for both the pharmaceutical and biotechnology industries.

The bioinformatics market is divided into three primary product categories: bioinformatics platforms, bioinformatics services, and bio-content management. Among these, the bioinformatics services segment is expected to grow at the fastest rate, with a projected CAGR of 14.6% during the forecast period. Genomics has been the primary application area for bioinformatics, focusing on the analysis of entire DNA sequences. The increasing availability of genetic data, especially through next-generation sequencing (NGS) technologies, is driving demand for bioinformatics services, both in genomic research and clinical applications.

For instance, in July 2021, the National Institute of Technology in Rourkela, India, launched the Centre for Bioinformatics and Computational Biology (CBCB). This center focuses on the development of biomarkers and therapeutic strategies for various diseases using big data analytics, further boosting bioinformatics research and market growth, particularly in emerging markets.

The bioinformatics platforms segment is also expected to experience significant growth, driven by the increasing volume and complexity of biological data, the growing demand for personalized medicine, and the rise of cloud computing. The adoption of cloud-based platforms in bioinformatics enables better data sharing and collaboration between academic institutions, research organizations, and healthcare providers. Additionally, advancements in sequencing technologies continue to propel the demand for bioinformatics platforms.

Furthermore, the introduction of new and innovative technologies is expected to drive market expansion. For example, in June 2022, My Intelligent Machines (MIMs) launched software designed for drug development in oncology. Similarly, in March 2022, ARUP launched Rio, a bioinformatics analytics platform that streamlines results for next-generation sequencing tests. These developments highlight the increasing integration of bioinformatics into drug discovery and diagnostic workflows, further contributing to the market’s growth.

Order a free sample PDF of the Bioinformatics Market Intelligence Study, published by Grand View Research.

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours.��

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[deshpandeisha]

Whole Exome Sequencing Market Growth and Size Analysis

The global Whole Exome Sequencing Market size was USD 1,966.6 Million in 2021 and is expected to register a revenue CAGR of 25.1% during the forecast period, according to latest analysis by Emergen Research. Major factors influencing market revenue growth include the increased prevalence of chronic and uncommon conditions, as well as the rising need for individualised therapy, next-generation sequencing, and genomics Research & Development (R&D).

The latest research report by Emergen Research, named ‘Global Whole Exome Sequencing Market. The report provides a detailed outlook on how the pandemic has affected the key segments of the Whole Exome Sequencing Market industry. The report includes an in-depth impact analysis of the COVID-19 pandemic on the overall Whole Exome Sequencing Market industry. It also offers valuable data to assist the investors in formulating strategic business investment plans and capitalize on the emerging growth prospects in the Whole Exome Sequencing Market  

Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/790

Competitive Terrain:

The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Whole Exome Sequencing market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic.

The leading market contenders listed in the report are:

Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Hoffman-La Roche AG, Eurofins Scientific Group, GENEWIZ, Inc., Knome, Inc., Macrogen, Inc., Ambry Genetics Corp., Beijing Genomics Institute

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/whole-exome-sequencing-market

For the purpose of this report, Emergen Research has segmented the global whole exome sequencing market based on product, end user, application, and region:

Product Outlook (Revenue, USD Million; 2019-2030)

Systems

Kits

Services

End User Outlook (Revenue, USD Million; 2019-2030)

Nutritional  

Research Center

Academic and Government Institutions

Hospitals and Clinics

Pharmaceutical and Biotechnology Companies

Others

Application Outlook (Revenue, USD Million; 2019-2030)

Diagnostics

Drug Discovery and Development

Personalized Medicine

Agriculture and Animal Research

Others

The various regions analyzed in the report include:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Key Objectives of the Report:

Analysis and estimation of the Whole Exome Sequencing Market size and share for the projected period of 2022-2030

Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape

Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Whole Exome Sequencing Market

Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments

Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities

[surajmarathedb1]

PHARMACOGENETIC TESTING MARKET Growth, Industry Size-Share, Global Trends, Key Players Strategies and Upcoming Demand

Data Bridge Market Research analyses that the PHARMACOGENETIC TESTING MARKET will project a compound annual growth rate (CAGR) of 8.00% during the forecast period of 2022-2028.

A world class PHARMACOGENETIC TESTING MARKET research report is formulated with the finest and advanced tools of collecting, recording, estimating and analysing market data. With the systematic and comprehensive market research study, this market research report offers the facts associated with any subject in the field of marketing for Healthcare industry. It gives superior ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. This PHARMACOGENETIC TESTING MARKET report has been prepared by considering several fragments of the present and upcoming market scenario.

PHARMACOGENETIC TESTING MARKET Scope and Market Size

The pharmacogenetic testing market is segmented on the basis of type, sample, therapeutic area, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.

On the basis of type, the pharmacogenetic testing market is segmented into single-gene tests, array-based tests, whole-genome sequencing, and NGS and whole-exome sequencing.

On the basis of the sample, the pharmacogenetic testing market is segmented into blood and saliva.

On the basis of therapeutic area, the pharmacogenetic testing market is segmented into oncology, neurology, cardiology, genomics, immunology and hypersensitivity, and others.

On the basis of distribution channels, the pharmacogenetic testing market is segmented into hospital pharmacies, retail pharmacies, mail-order pharmacies, direct-to-customer services.

Get the Free sample copy of the report here:

Some of the key questions answered in this report:

How has the PHARMACOGENETIC TESTING MARKET performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the PHARMACOGENETIC TESTING MARKET?

What are the key regional markets?

What are the key driving factors and challenges in the industry?

What is the structure of the PHARMACOGENETIC TESTING MARKET and who are the key players?

Market Analysis and Insights:  PHARMACOGENETIC TESTING MARKET

The pharmacogenetic testing market is expected to witness market growth at a rate of 8.70% in the forecast period of 2021 to 2028. Data Bridge Market Research report on the pharmacogenetic testing market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the levels of healthcare expenditure is escalating the growth of the pharmacogenetic testing market.

A pharmacogenetic test, which is also referred to as the drug-gene test, is utilized to study and determine the interactions of drugs and the genetic make-up of the individual. It has been observed that several people react differently with drugs depending upon the expression of the genes induced by the drug.

PHARMACOGENETIC TESTING MARKET - Regional Level Analysis

The countries covered in the pharmacogenetic testing market report are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

PHARMACOGENETIC TESTING MARKET - Share Analysis: 

The pharmacogenetic testing market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the pharmacogenetic testing market.

Key player - PHARMACOGENETIC TESTING MARKET 

Some of the major players operating in the PHARMACOGENETIC TESTING MARKET are Sonic Healthcare, Genelex, GENEWIZ, Rxight; 23andMe, Inc., PGXT, OneOme, LLC, Mako Medical Laboratories, LLC, Myriad Genetics, Inc., Bayer AG, BGI, Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Luminex Corporation, Eurofins Scientific, Illumina, Inc., Thermo Fisher Scientific Inc. and PerkinElmer Inc.

Get Full Access of Report@

MAJOR TOC OF THE REPORT

Chapter One: Introduction

Chapter Two: Scope and Market Size

Chapter Three: Analysis and Insights

Chapter Four: Country Level Analysis

Chapter Five: Share Analysis

Chapter Six: Key player

Get TOC Details:

Top Trending Reports:

Human Microbiome Market

Healthcare Information Technology (It) Outsourcing Market

Africa Point-Of-Care Diagnostics Market

Europe Point-Of-Care Diagnostics Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-386.8-2818

Email: Sopan.gedam@databridgemarketresearch.com

[pathologylab]

Clinical Exome Sequencing Panel provides a comprehensive identification of suspected complex genetic disorder.

#clincalexome #exome #exomesequencing #sequencing #genetictesting #Breastcancer

Connect Today - #GENES2ME

18001214030

exome, clinical exome, exome sequencing, clinical exome sequencing, exome sequencing in india, Genetic Testing, Genetics,

[top-market-research]

Whole Exome Sequencing Market  Growth, Drivers and Restraint Research Report by 2027

The in-depth study on the Whole Exome Sequencing Market covers a comprehensive analysis of the historical data, present and emerging market trends, technological advancements, and the overall market scenario. The report titled Global Whole Exome Sequencing Market published by Reports and Data analyze the current market scene, market share, growth rate, future trends, market drivers, opportunities, and challenges, risks and entry barriers. The report includes a comprehensive assessment of the positive and negative factors influencing the growth and trends of the market.  

The Global Whole Exome Sequencing Market size is estimated to reach USD 525.74 million by 2027 from USD 219.89 million in 2019, delivering a CAGR of 11.6% through the forecast period.

The report considers COVID-19 as a key market contributor. The report describes in detail the effect of the COVID-19 pandemic on the major segments of the Whole Exome Sequencing Market sector. The pandemic has affected the Whole Exome Sequencing Market sector dynamically and the report covers the changes in demands and trends in the market. The report studies threats and challenges the industry players will have to face due to the changes induced by COVID-19 pandemic. Furthermore, the report provides a detailed description of the COVID-19 impact on the overall growth of the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3588

The report is an all-inclusive document containing a thorough assessment of the top market players operating in the industry and controlling a significant share of the market. A breakdown analysis of the competitive landscape comprising of expansion tactics and strategic alliances adopted by the companies are offered in the report. The report covers a detailed assessment of mergers & acquisitions, product launches, partnerships & agreements, joint ventures, and collaborations, among others happening between the prominent industry players.

Key Players Operating in the Market and Profiled in the Report are:

BGI, Ambry Genetics, Eurofins Genomics Inc., Life Technologies, Illumina, Inc., and GENEWIZ, Inc.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3588

The reports presents encyclopedic company profiles of the leading participants of the Whole Exome Sequencing Market industry to allow the reader to gain a better understanding of the competitive landscape to help in formulating better decisions and investment strategies. It also covers SWOT analysis and Porter’s Five Forces analysis to impart a better understanding of the key players operating in the market.

Additionally, the report consists a detailed analysis of the segmentation of the Whole Exome Sequencing Market based on product types and end-use/application offered in the Whole Exome Sequencing Market. The report an exhaustive summary of the product and application landscape of the industry along with details about the segmented expected to show significant growth in the upcoming years.

Based on the Technology, the Whole Exome Sequencing Market is segmented into

Sequencing by Synthesis (SBS)

ION Semiconductor Sequencing

Other Technologies

Based on the application spectrum, the Whole Exome Sequencing Market is segmented into

Diagnostics

Cancer Diagnostics

Monogenic (Mendelian) Disorders

Monogenic Types of Diabetes

Others

Drug Discovery and Development

Personalized Medicine

Agriculture & Animal Research

Others

Common Diseases and Complex Disorders

Movement Disorders

HIV

To know more about the report, visit @ https://www.reportsanddata.com/report-detail/whole-exome-sequencing-market

The report provides an extensive detailing of the market share and size of the Whole Exome Sequencing Market industry in the key geographical regions. Based on the regional breakdown, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In-depth regional analysis covers:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/3588

Browse Related Reports –

Photomedicine Market Growth

Cervical Cancer Diagnostic Market

Photomedicine Market Drivers

Bioinformatics Market Manufacturers

Blood Culture Tests Market Revenue

Non-Alcoholic Steatohepatitis (NASH) Market Segments

Thank you for reading our report. For further query or inquiry, kindly get in touch with us and our team will ensure your requirements for the reports are met.

[dnalabs2-blog]

NIPT Test

Clinical Exome Test

DNA labs India is Ranked as India's no1 Genetic DNA Test Lab with 3000 sample collection centers across India for DNA Test, NIPT Test, BRCA Test, Genetic Test, Paternity Test and  Clinical Exome Test. DNA Labs India has regional DNA Test sample collection centers in Mumbai Delhi Bangalore Hyderabad Ahmedabad Chennai Kolkata Surat Pune Jaipur Visakhapatnam Kanpur Nagpur Lucknow Thane Bhopal Indore Pimpri Chinchwad Patna Vadodara Ghaziabad Ludhiana Agra Nashik Faridabad Meerut Rajkot Kalyan Dombivli Vasai Virar Varanasi Srinagar Aurangabad Dhanbad Amritsar Navi Mumbai Allahabad Howrah Ranchi for DNA Test, NIPT Test, BRCA Test, Genetic Test, Paternity Test and  Clinical Exome Test. DNA Test Details : DNA TESTING Which were the primary methods of scientific identification used before DNA testing became widespread. As a result, if improved DNA testing techniques and more reliable testing protocols, forensic scientists and DNA lab If the DNA test results were used at the trial, it is important to understand how the results were used in the DNA case and whether they were the changes in expertise and technology available for forensic DNA testing may require the reexamination. NIPT Test Details: With Noninvasive Prenatal Testing (NIPT): Applied Genomics in Prenatal Screening and Diagnosis, Dr Lieve Page-Christiaens and Dr Hanns-Georg Klein have compiled the first authoritative volume on cfDNA NIPT methods and their clinical BRCA Test Details:  Since genetic testing of the BRCA genes first became clinically available in 1996, the published literature on appropriate medical management for patients who test positive has evolved dramatically. Similarly, the approach to offering genetic Genetic Test Details: This arrangement works well and is generally adhered to throughout clinical practice, even for esoteric testing areas such as molecular pathology and diagnostic molecular genetics". Among the extraordinary diversity of techniques Paternity Test Details: The most common form of these tests is the genetic paternity test. Paternity testing is a particular instance of a range of identity tests that determine relationships between people for immigration, succession to estates, identification of human Clinical Exome Test Details: As with any other clinical genetic testing, the content of clinical exome sequencing reports follows the current CLIA regulations and requirements (42 CFR §493.1291) and CAP recommendations

[shital1998]

Genetic Testing Market – Global Opportunity Analysis and Industry Forecast (2022-2029)

Meticulous Research®—a leading global market research company, published a research report titled, ‘Genetic Testing Market By Product (Consumables, Reagents, Instruments, Services), Test Type (Diagnostic, Prenatal, Carrier, Newborn, Preimplantation), Method (Molecular, Chromosomal), End User (Hospitals, Diagnostic Laboratories) - Global Forecast to 2029.’

According to this latest publication from Meticulous Research®, the genetic testing market is expected to grow at a CAGR of 11.6% from 2022 to reach $43.3 billion by 2029. The growth of this market is attributed to factors such as favorable government initiatives for promoting genetic testing, increasing prevalence of genetic disorders, increased need for early disease detection & prevention, increasing applications of genetic testing in oncology, and decreasing cost of sequencing procedures. In addition, the growing scenario of genetic direct-to-consumer genetic testing and the emerging field of genetic counseling is expected to provide significant growth opportunities for this market.

However, factors such as the high cost of genetic testing and the social and ethical implications of genetic testing are restraining the growth of this market to a notable extent. In addition, factors such as low chances of positive, actionable mutations and genetic data privacy & security concerns are the major challenges to the growth of this market.

Genetic Testing Market: Future Outlook

The genetic testing market is segmented based on product, test type, method, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Download Research Sample https://www.meticulousresearch.com/download-sample-report/cp_id=5370

Scope of the Report:

Genetic Testing Market, by Product & Service

·         Consumables & Reagents

·         Instruments

·         Services

Genetic Testing Market, by Test Type

·         Diagnostic Testing

·         Prenatal Testing

·         Carrier Testing

·         Newborn Screening

·         Preimplantation Testing

·         Other Test Types (Other test types include forensic testing, microorganism genomics, and posthumous (testing of post-mortem tissues etc.)

Genetic Testing Market, by Method

·         Molecular Tests

·         Chromosomal Tests

·         Biochemical Tests

Genetic Testing Market, by End User

·         Hospitals & Clinics

·         Diagnostic Laboratories

·         Academic & Research Institutes

·         Others End Users (Other end users include contract research organizations, forensic laboratories, pharma & biotech companies, government laboratories, etc.)

Genetic Testing Market, by Geography

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    France

o    U.K.

o    Italy

o    Spain

o    Rest of Europe (RoE)

·         Asia-Pacific

o    China

o    Japan

o    India

o    Rest of APAC (RoAPAC)

·         Latin America

·         Middle East & Africa

Speak with Our Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5370

Based on product, in 2022, the consumables & reagents segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the recurrent use of reagents & consumables, availability of a wide range of genetic tests, recent product launches, and increased awareness about the advantages of genetic testing.

Based on test type, in 2022, the diagnostic testing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the high prevalence of chronic diseases such as cancer, technological advancements in genomic-based diagnostic testing, and the demand for early disease diagnosis.

Based on method, in 2022, the molecular segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the ability to detect the mutation at single nucleotide resolution with cheaper, faster, and with the utmost accuracy by using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.

In 2022, based on end user, the hospitals & clinics segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the high volume of genetic tests performed in hospitals & clinics and the high demand for early disease diagnosis and treatment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa.

In 2022, North America is estimated to account for the largest share of the genetic testing market, followed by Europe and Asia-Pacific. North America’s large market share is attributed to the factors such as high healthcare expenditure, favorable reimbursement scenario, high awareness among patients about genetic testing, and increased support and investments to enhance genome sequencing infrastructure in the region.

Access full Report Description, TOC, Table of Figure, Chart, etc: https://www.meticulousresearch.com/product/genetic-testing-market-5370

Key Players

The key players operating in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), 23andMe, Inc. (U.S.), Foundation Medicine, Inc. (U.S.) (Subsidiary of Roche Holding AG), Rosetta Genomics Ltd. (U.S.), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.) and Invitae Corporation (U.S.).

Key questions answered in the report-

·  Which are the high-growth market segments in terms of product, test type, method, end user, and region/country?

·  What was the historical market size for genetic testing across the globe?

·  What are the market forecasts and estimates for the period 2022–2029?

·  What are the major drivers, restraints, opportunities, and challenges in the global genetic testing market?

·  Who are the major players in the genetic testing market?

·  How is the competitive landscape, and who are the market leaders in the global genetic testing market?

·  What are the recent developments in the global genetic testing market?

·  What are the different strategies adopted by the major players in the global genetic testing market?

·  What are the geographical trends and high-growth regions/countries?  

Contact Us:

Meticulous Research

®

Email- 

sales@meticulousresearch.com

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn- 

https://www.linkedin.com/company/meticulous-research

[healthcaredbmrnews]

The whole exome sequencing market is expected to gain market growth in the forecast period of 2021 to 2028.

[dbmrmarketnews]

The whole exome sequencing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 11.4% in the forecast period of 2021 to 2028. The increase in number of research and development activities to enhance scientific applications is escalating the growth of whole exome sequencing market.

[cricsart]

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

[reallyzealousnight]

Next Generation Sequencing (NGS) Market 2028

Next Generation Sequencing Market by Product (Consumables, Platforms, Services, and Nerve Blockers), Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Agriculture and Animal Research, and Other Applications), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Pyrosequencing, Single Molecule Real Time Sequencing, and Other Technologies)

The global market for next-generation sequencing (NGS) is expected to grow at a CAGR of 16.2 percent from 2019 to $10.35 billion by 2025.

Next Generation Sequencing (NGS) is a technique for determining the nucleotide sequence in a DNA sample. It allows for the rapid and low-cost sequencing of DNA or RNA. This market's expansion is being driven primarily by technological advancements in sequencing procedures, an increase in genome mapping programmes, and an increase in drug discovery platforms that require NGS technology. Furthermore, the growing number of government initiatives for large-scale genomic sequencing projects, as well as the emergence of cloud computing as a potential data management service, are driving NGS product adoption.

Download Research PDF :- https://www.meticulousresearch.com/request-sample-report/cp_id=5040

The study categorizes the next-generation sequencing market into the following segments and subsegments:

BY PRODUCT 

Exome & Targeted Resequencing & Custom Panels

 Whole-Genome Sequencing & De Novo Sequencing

 RNA Sequencing

 Other Sequencing Services

Library Preparation & Target Enrichment

 Quality Control

Novaseq Systems

  Nextseq Systems

  Miseq Systems

  Miniseq Systems

  iSeq Systems 

  ION PGM Systems

  ION Proton Systems

  ION Genestudio Systems

  Ion Torrent Genexus Systems

   Data Analysis Services

 NGS Data Analysis Software & Workbenches

 NGS Storage, Management, & Cloud Computing Solutions

BY TECHNOLOGY

Sequencing by Synthesis

ION Semiconductor Sequencing

Nanopore Sequencing

Single-Molecule Real-Time Sequencing

Other Technologies

BY APPLICATION

Cancer Diagnostics

 Infectious Disease Diagnostics

 Reproductive Health Diagnostics

 Other Diagnostic Applications

BY END USER

Academic Institutes & Research Centers

Pharmaceutical & Biotechnology Companies

Hospitals & Clinics

Other End Users

BY REGION

 US

 Canada

 Germany

 UK

 France

 Italy

 Spain

 Netherlands

 Rest of Europe

 China

 Japan

 India

 Australia

 Rest of Asia Pacific

 Brazil

 Mexico

 Rest of Latin America

Insights into End-Use Industry

In 2020, the academic research end-use segment held the largest share of more than 53%. From 2021 to 2028, the segment is expected to grow at a steady CAGR. This expansion can be attributed to the use of NGS solutions in research projects conducted at universities and research centres. Furthermore, scholarships for Ph.D. projects in NGS are expected to drive demand for NGS products and services, resulting in profitable growth over the next few years.

Get More Insights :- https://www.meticulousresearch.com/product/next-generationg-sequencing-market-5040

Furthermore, countries such as Germany and the United Kingdom have a number of universities that provide NGS applications and molecular biology courses. For instance, the Wageningen University & Research, the Netherlands offers NGS facilities and technologies that can be used in various applications.

The Report Answers The Following Key Questions:

·         How do advances in sequencing technologies influence the adoption of NGS products?

·         How are the industry's leaders incorporating technological advancements into their products?

·         Who are the top competitors in this market and what strategies do they employ to gain shares?

·         What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?

·         What are the major drivers, restraints, opportunities, challenges, and trends in the global next-generation sequencing market?

·         Who are the major players in various countries and what share of the global market do they hold?

Contact: Mr. Khushal Bombe Meticulous Market Research Inc. 1267 Willis St, Ste 200 Redding,  California, 96001, U.S. USA: +1-646-781-8004 Europe : +44-203-868-8738 APAC: +91 744-7780008 Email- sales@meticulousresearch.com 

[surajmarathedb1]

PHARMACOGENETIC TESTING MARKET Growth, Industry Size-Share, Global Trends, Key Players Strategies and Upcoming Demand

Data Bridge Market Research analyses that the PHARMACOGENETIC TESTING MARKET will project a compound annual growth rate (CAGR) of 8.00% during the forecast period of 2022-2028.

A world class PHARMACOGENETIC TESTING MARKET research report is formulated with the finest and advanced tools of collecting, recording, estimating and analysing market data. With the systematic and comprehensive market research study, this market research report offers the facts associated with any subject in the field of marketing for Healthcare industry. It gives superior ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. This PHARMACOGENETIC TESTING MARKET report has been prepared by considering several fragments of the present and upcoming market scenario.

PHARMACOGENETIC TESTING MARKET Scope and Market Size

The pharmacogenetic testing market is segmented on the basis of type, sample, therapeutic area, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.

On the basis of type, the pharmacogenetic testing market is segmented into single-gene tests, array-based tests, whole-genome sequencing, and NGS and whole-exome sequencing.

On the basis of the sample, the pharmacogenetic testing market is segmented into blood and saliva.

On the basis of therapeutic area, the pharmacogenetic testing market is segmented into oncology, neurology, cardiology, genomics, immunology and hypersensitivity, and others.

On the basis of distribution channels, the pharmacogenetic testing market is segmented into hospital pharmacies, retail pharmacies, mail-order pharmacies, direct-to-customer services.

Get the Free sample copy of the report here:

Some of the key questions answered in this report:

How has the PHARMACOGENETIC TESTING MARKET performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the PHARMACOGENETIC TESTING MARKET?

What are the key regional markets?

What are the key driving factors and challenges in the industry?

What is the structure of the PHARMACOGENETIC TESTING MARKET and who are the key players?

Market Analysis and Insights:  PHARMACOGENETIC TESTING MARKET

The pharmacogenetic testing market is expected to witness market growth at a rate of 8.70% in the forecast period of 2021 to 2028. Data Bridge Market Research report on the pharmacogenetic testing market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the levels of healthcare expenditure is escalating the growth of the pharmacogenetic testing market.

A pharmacogenetic test, which is also referred to as the drug-gene test, is utilized to study and determine the interactions of drugs and the genetic make-up of the individual. It has been observed that several people react differently with drugs depending upon the expression of the genes induced by the drug.

PHARMACOGENETIC TESTING MARKET - Regional Level Analysis

The countries covered in the pharmacogenetic testing market report are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

PHARMACOGENETIC TESTING MARKET - Share Analysis: 

The pharmacogenetic testing market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the pharmacogenetic testing market.

Key player - PHARMACOGENETIC TESTING MARKET 

Some of the major players operating in the PHARMACOGENETIC TESTING MARKET are Sonic Healthcare, Genelex, GENEWIZ, Rxight; 23andMe, Inc., PGXT, OneOme, LLC, Mako Medical Laboratories, LLC, Myriad Genetics, Inc., Bayer AG, BGI, Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Luminex Corporation, Eurofins Scientific, Illumina, Inc., Thermo Fisher Scientific Inc. and PerkinElmer Inc.

Get Full Access of Report@

MAJOR TOC OF THE REPORT

Chapter One: Introduction

Chapter Two: Scope and Market Size

Chapter Three: Analysis and Insights

Chapter Four: Country Level Analysis

Chapter Five: Share Analysis

Chapter Six: Key player

Get TOC Details:

Top Trending Reports:

Human Microbiome Market

Healthcare Information Technology (It) Outsourcing Market

Africa Point-Of-Care Diagnostics Market

Europe Point-Of-Care Diagnostics Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-386.8-2818

Email: Sopan.gedam@databridgemarketresearch.com

[pathologylab]

A rare #genetic #metabolic #disorder which causes disruption in the body's ability to break down sugars is known as #Sanfilippo syndrome. It affects 1 in 100,000 live births in India. The symptoms do not start appearing until 2-6 years old. Early #diagnosis with the help of various tests including a genetic test (Symptom-based #Clinical Exome #Sequencing or Whole #Exome Sequencing) can help provide the child with better treatment and manage the condition. On this "World Sanfilippo #Awareness Day" spread the knowledge and get it touch with us for "Exome Sequencing" Visit. https://t2m.io/exome For more details, Call us at 18001214030 or drop us an email at social@genes2me.com for an Appointment #Syndrome #SanfilippoAwareness #Genes2Me #G2M #Genes #Testing #GeneticTesting #AntigenTest #RTPCR #HealthCare #Health